California-based AI firm Suki has raised $70 million in new funding, led by Hedosophia, bringing its total to $165 million.

Pfizer is set to present initial findings from its CULTIVATE study of Velsipity (etrasimod) in Crohn’s disease (CD) at UEG ...

Switzerland-based KeyBioscience and US pharma major Eli Lilly have extended their collaboration on dual amylin calcitonin ...

Swiss generic and biosimilar medicines major Sandoz today announced that it has launched a generic paclitaxel formulation in ...

The Food and Drug Administration (FDA) approved Genentech's Itovebi (inavolisib), in combination with palbociclib (Ibrance) ...

The UK's MHRA has approved Pfizer and BioNTech's updated COVID-19 vaccine, Comirnaty (KP.2), for use in adults. This approval ...

Berlin, Germany-based Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines ...

German cancer specialist Immatics has priced a $150 million public offering with Jefferies, BofA Securities, and Leerink as ...

South Korea’s Samsung Bioepis has released its Fourth Quarter 2024 Biosimilar Market Report, marking the seventh-edition of ...

Danish dermatology specialist Leo Pharma has revealed plans to cut more jobs, marking the company’s fourth workforce ...

Cambridge, Massachusetts-based RNA specialist CAMP4 Therapeutics (Nasdaq: CAMP) is set to raise $75 million as it goes public ...

Gritstone bio has filed for bankruptcy following disappointing Phase II data from its study of the personalized neoantigen ...